Skip to main content
Clinical Trials/NCT01464853
NCT01464853
Terminated
Phase 3

Effect of Enteral Nutrition Support for Critically Ill Patients

Abbott Nutrition9 sites in 1 country84 target enrollmentApril 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Respiratory Distress Syndrome,Adult
Sponsor
Abbott Nutrition
Enrollment
84
Locations
9
Primary Endpoint
Oxygenation status improvement
Status
Terminated
Last Updated
14 years ago

Overview

Brief Summary

To determine whether specialized enteral nutrition support can improve oxygenation status in critically ill patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) comparing to a standard enteral nutritional formula.

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
May 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or non-pregnant female.
  • ALI or ARDS
  • PaO2/FiO2 \> 100 and ≤ 300 torr.
  • Evidence of bilateral pulmonary infiltrates/opacity on chest radiograph.
  • Enteral access
  • Systemic inflammatory response syndrome (SIRS) - two or more of the following must be present:
  • Body temperature less than 36°C or greater than 38°C
  • Heart rate \> 90 beats per minute
  • Tachypnea with \> 20 breaths per minute; or an arterial partial pressure of carbon dioxide \< 4.3 kPa (32 mmHg)
  • White blood cell count \< 4000 cells/mm³ or \> 12,000 cells/mm³; or the presence of \> 10% immature neutrophils.

Exclusion Criteria

  • Dialysis for renal failure
  • Unable to initiate Enteral feeding within 48 hours since all inclusion criteria met.
  • Anticipated life expectancy less than 24 hours.
  • Patient with severe chronic liver disease
  • Neuromuscular disease that impairs ability to ventilate without assistance
  • Head trauma and/or drowning with a Glasgow coma score of 5
  • Receiving intravenous lipid emulsions from parenteral nutrition within 12 hours of baseline.
  • Receiving propofol
  • Airway reconstructive surgery.
  • Malignancy or irreversible disease for which 6-month mortality is greater than 50%.

Outcomes

Primary Outcomes

Oxygenation status improvement

Time Frame: 28 days

Secondary Outcomes

  • Vitamin D status(28 days)
  • Length of ventilation(28 days)
  • Length of ICU stay(28 days)
  • Incidence of organ failures(28 days)
  • Incidence of ventilator-associated pneumonia(28 days)
  • Mortality(28 days)
  • Glycemic control(28 days)
  • Inflammation(28 days)

Study Sites (9)

Loading locations...

Similar Trials